Recursion announced the full enrollment of its Phase 2 SYCAMORE clinical trial evaluating REC-994, a potentially first-in-class, orally bioavailable small molecule for the treatment of CCM. The Phase 2 trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994. The primary outcome is specific to safety and tolerability, measured by adverse events. The secondary outcomes center on efficacy, including clinician- and patient-reported outcomes, imaging of CCM lesions, the impact of acute stroke, as well as exploratory biomarkers.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RXRX:
- Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
- Recursion to Participate in Upcoming Investor Conferences
- Altitude Lab Relocates to Gateway’s BioHive Hub
- Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
- Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results